| William Matthew Hargrove, CRNA | |
|
1224 Trotwood Ave, Columbia, TN 38401 | |
| (866) 612-5074 | |
| Not Available |
| Full Name | William Matthew Hargrove |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 12 Years |
| Location | 1224 Trotwood Ave, Columbia, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487903985 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 16760 (Tennessee) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Resource Anesthesiology Associates Of Tn Pc | 8527419092 | 23 |
News Archive
The U.S. Food and Drug Administration (FDA) is warning U.S. consumers not to use the emergency birth control medicine labeled as Evital.
Infection is the most common complication of surgery and occurs at a rate of 1-15%. A group of experts from the Surgical Infection Society recently convened to discuss how to optimize the preoperative surgical site cleaning done by the patient to minimize the risk of infection.
Patients who suffer from infective endocarditis (IE) and struggle with substance use disorder (SUD) have a 240% increased risk of dying within 6 months to 5 years after valve surgery compared to other IE patients, according to a study published online today in The Annals of Thoracic Surgery.
Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.
› Verified 2 days ago
| Entity Name | Cardiovascular Anesthesiologists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912953381 PECOS PAC ID: 4688571045 Enrollment ID: O20031215000805 |
News Archive
The U.S. Food and Drug Administration (FDA) is warning U.S. consumers not to use the emergency birth control medicine labeled as Evital.
Infection is the most common complication of surgery and occurs at a rate of 1-15%. A group of experts from the Surgical Infection Society recently convened to discuss how to optimize the preoperative surgical site cleaning done by the patient to minimize the risk of infection.
Patients who suffer from infective endocarditis (IE) and struggle with substance use disorder (SUD) have a 240% increased risk of dying within 6 months to 5 years after valve surgery compared to other IE patients, according to a study published online today in The Annals of Thoracic Surgery.
Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.
› Verified 2 days ago
| Entity Name | Maury Regional Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861479545 PECOS PAC ID: 4688569718 Enrollment ID: O20040330001709 |
News Archive
The U.S. Food and Drug Administration (FDA) is warning U.S. consumers not to use the emergency birth control medicine labeled as Evital.
Infection is the most common complication of surgery and occurs at a rate of 1-15%. A group of experts from the Surgical Infection Society recently convened to discuss how to optimize the preoperative surgical site cleaning done by the patient to minimize the risk of infection.
Patients who suffer from infective endocarditis (IE) and struggle with substance use disorder (SUD) have a 240% increased risk of dying within 6 months to 5 years after valve surgery compared to other IE patients, according to a study published online today in The Annals of Thoracic Surgery.
Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.
› Verified 2 days ago
| Entity Name | Resource Anesthesiology Associates Of Tn Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316724073 PECOS PAC ID: 8527419092 Enrollment ID: O20240109002456 |
News Archive
The U.S. Food and Drug Administration (FDA) is warning U.S. consumers not to use the emergency birth control medicine labeled as Evital.
Infection is the most common complication of surgery and occurs at a rate of 1-15%. A group of experts from the Surgical Infection Society recently convened to discuss how to optimize the preoperative surgical site cleaning done by the patient to minimize the risk of infection.
Patients who suffer from infective endocarditis (IE) and struggle with substance use disorder (SUD) have a 240% increased risk of dying within 6 months to 5 years after valve surgery compared to other IE patients, according to a study published online today in The Annals of Thoracic Surgery.
Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William Matthew Hargrove, CRNA Po Box 235022, Montgomery, AL 36123 Ph: (866) 612-5074 | William Matthew Hargrove, CRNA 1224 Trotwood Ave, Columbia, TN 38401 Ph: (866) 612-5074 |
News Archive
The U.S. Food and Drug Administration (FDA) is warning U.S. consumers not to use the emergency birth control medicine labeled as Evital.
Infection is the most common complication of surgery and occurs at a rate of 1-15%. A group of experts from the Surgical Infection Society recently convened to discuss how to optimize the preoperative surgical site cleaning done by the patient to minimize the risk of infection.
Patients who suffer from infective endocarditis (IE) and struggle with substance use disorder (SUD) have a 240% increased risk of dying within 6 months to 5 years after valve surgery compared to other IE patients, according to a study published online today in The Annals of Thoracic Surgery.
Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.
› Verified 2 days ago
Elizabeth Foster, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1224 Trotwood Ave, Columbia, TN 38401 Phone: 931-381-1111 | |
Kendra Rennell, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1224 Trotwood Ave, Columbia, TN 38401 Phone: 931-381-1111 | |
Amanda R Voss, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1224 Trotwood Ave, Columbia, TN 38401 Phone: 877-319-7141 Fax: 877-243-2920 | |
Lisa R Lovett, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1224 Trotwood Ave, Columbia, TN 38401 Phone: 931-381-1111 | |
Anthony Scott Sorrell, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1224 Trotwood Ave, Columbia, TN 38401 Phone: 931-381-1111 | |
Benjamin T Hargrove, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1224 Trotwood Ave, Columbia, TN 38401 Phone: 931-381-1111 Fax: 931-490-7064 |